Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy.
Elise C. Tarbi, Ian Bhatia, Nabil Balach, Suzannah Buehler, Magdalena Demeo-Meres, Cailin Gramling, Tej Thambi, Julia Hart, Maija Reblin, Donna M Rizzo, Robert Gramling, Manish Agrawal, Emily Manetta
Healthcare (Basel, Switzerland) June 5, 2026 DOI: 10.3390/healthcare14111589 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study using direct observation coding of clinical trial recordings Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Participants with advanced cancer in a Phase 2 clinical trial of psilocybin-assisted therapy |
| Intervention | Psilocybin-assisted therapy |
| Topics | Psilocybin Psychedelic-assisted therapy |
| Keywords | Awe Interpersonal communication Psychedelics |
| Key findings | Awe narration during psilocybin-assisted therapy can be reliably identified by human coders using definitional criteria, with coders' confidence significantly higher when vastness is present. |
Abstract
Background: Understanding the benefits of psychedelic-assisted therapy (PAT) will require scientific attention to the causal interaction between the therapeutic context and process. Measuring what actually happens during PAT in large-scale studies will be an essential component of this work.
Objective: We aim to develop and preliminarily evaluate the feasibility and reliability of a direct observation coding system for narrations of awe experiences during PAT, one hypothesized therapeutic mechanism.
Methods: We analyzed 32 PAT clinical trial encounter recordings involving eight participants from a Phase 2 clinical trial study of psilocybin-assisted therapy in advanced cancer. Using a conceptually grounded structured codebook, two human coders independently identified start and stop times for moments exhibiting definitional characteristics of awe narration, including expressions of vastness, need for accommodation and ineffability. We used coder agreement and degree of confidence to refine the coding system.
Results: During 16,760 total minutes of video, coders collectively recorded 246 moments of awe narration. Of those moments, 42% (104/246) were identified by one coder and 58% (142/246) by two coders. Coders felt substantially more confident in their judgments about a moment of awe when vastness was present compared to when vastness was absent (OR: 4.3; 95% CI: 2.4, 7.8). Iterative refinement of the coding system led to accommodation being operationalized as two distinct components: an initial cognitive disruption followed by variable engagement in the process of accommodation.
Conclusions: Awe narration is directly observable using explicit definitional criteria. This work provides the empirical foundation for scalable coding systems of awe narration during PAT.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Awe narration during psilocybin-assisted therapy can be reliably identified by human coders, with confidence significantly higher when vastness was present.
Synthesized
Comparable studies
Other non-randomized and open-label trials on psilocybin and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression | 2017 | Open-label trial | n = 20 |
| Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder | 2021 | Open-label study | n = 24 |
| HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Cancer patients with a DSM-5 depressive disorder (major depressive disorder or... | 2023 | Open-label feasibility and safety pilot study | n = 12 |
| Group psychedelic therapy: empirical estimates of cost-savings and improved access Adults with PTSD or major depressive disorder eligible for psychedelic-assisted therapy... | 2023 | Comparative cost analysis using trial data and published estimates | |
| Increased low-frequency brain responses to music after psilocybin therapy for depression. Patients with treatment-resistant depression | 2023 | Open-label trial | n = 19 |